Douglas Laboratories launches Sereniten Plus

February 13, 2014 — Douglas Laboratories recently announced the addition of Sereniten Plus to its existing line of products available in the U.S. Developed by Penny Kendall-Reed, ND, a specialist in metabolic disorders who is also a member of the Douglas Laboratories Clinical Advisory Board, Sereniten Plus rapidly became a popular stress management support choice for Canadian healthcare practitioners.

“Douglas Laboratories Canada has had great success partnering with Dr. Kendall-Reed to educate and promote Sereniten Plus in 2012 and 2013. This product, now available throughout North America, is the most successful new product launch to date,” said Andrew Halpner PhD, vice president, Product Development and Technical Services at Douglas Laboratories.

“Sereniten Plus was developed to promote an anxiolytic effect — supporting mental and physical stress,”† said Dr. Kendall?Reed. “Lactium is the only supplemental ingredient I have found to lower glucocorticoid secretion and rebalance the Hypothalamic?Pituitary?Adrenal pathway.”†

The Sereniten Plus formula consists of a combination of Lactium, L?Theanine, and vitamin D to support the HPA axis and feedback loop for stress management and cortisol regulation. Lactium, a bioactive decapeptide, and L?Theanine have been shown to provide a calming effect without drowsiness and support normal sleep that is affected by stress.† It is also unique in how it increases the sensitivity of the hypothalamus to cortisol, thereby re?establishing the receptor sensitivity and feedback within the HPA axis.

Results from studies have shown that 30 days of supplementation with Lactium can result in lowered plasma cortisol levels and a reduction in stress related issues promoting digestion, cardiovascular, intellectual, emotional, and social wellbeing.†

Source: Douglas Laboratories

†These statements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure or prevent any disease.